Strong margins, volume-driven growth, strategic clarity—but ARPP weakness and new-hospital drag remain

Delivered 695.1 Cr, YoY growth 13.4%

120 bps margin expansion (18.2% to 19.4%), claim of +100 bps target met

Drug impact claimed at 1.5%; actual 13.4% + 1.5% ≈ 14.9%, approximately 15%

Broad-based growth confirmed via volume (+11%) and payor mix (non-institutional +17%)

Modest ARPP growth in line with inflation claim; case mix drag acknowledged

Strategic divestment completed end June 2026. Sharpens oncology focus; removes lower-margin non-core segment. Focus now purely on cancer care platform.

Non-institutional revenue +17% YoY; non-institutional mix 67% → 69%. Continued shift toward higher-margin cash and TPA patients vs institutional.

Impacted revenue -1.5% but margin-accretive (high value, low margin). Reflects conscious mix management; revenue impact offset by margin gain.

Interest costs expected to moderate. Finance cost drag on PAT to ease in coming quarters as leverage reduces.

Strategic shift toward higher-value cash/non-institutional, but absolute institutional revenue erosion in Gujarat. Market share loss or deliberate de-emphasis?

4 → 7 hospitals in >₹10 Cr/month bracket; 14 → 11 in ₹5–10 Cr bracket. Like-for-like growth data deferred to offline.

Whitefield (South) likely end FY28; Maharashtra (West) likely FY29. Two greenfield projects total.

₹170 Cr debt repaid from rights proceeds. Interest cost expected to moderate year-on-year. Will fund growth via mix of debt and internal accruals.

Remain confident of mid-teens growth from existing + new centers. Mix of volume, ARPP (in line with inflation), and operating leverage will drive revenue. No change in outlook.

Peaked losses in Q1 (₹7 Cr done, MR-LINAC commissioned July). Expect breakeven next few quarters. ESOP impact to be reported in Q2.

Q1 impact ~1.5% on revenue; margin-accretive (high value, low margin drugs). Will remain ~1.5% or marginal decline as higher-margin business replaces.

Work on manpower and fixed costs via automation, data analytics. Productivity improvements (clinical/nonclinical). Patient experience enhancements.

ARPP growth inline with inflation. Cannot break down further at this time.

Focus on building technology, clinical capabilities (CAR-T, BMT, robotic surgery, precision diagnostics). Invest in clinicians and advanced equipment for complex procedures.

Growth broad-based. Notably 3 hospitals moved from ₹5–10 Cr/month to >₹10 Cr/month bracket. Growth across all sizes.

340 beds across 25 centers; several centers mentioned, but many others (Baroda, Cuttack, Ranchi) have smaller additions (10–15 beds). Long tail of smaller expansions not detailed.

Q1 capex ₹75 Cr (₹35 growth, ₹40 maintenance). FY27 maintenance capex ~₹100 Cr.

Existing facilities can handle 75–80% utilization without growth being affected. Ample headroom across clusters.

Doubled down on sales & marketing (20%+ increase YoY). Currently 2.9% of sales; long-term target 2.5–2.6%.

Optimal 60–65% utilization by year 3–4. Currently early stages. Management expects monthly breakeven in FY27.

Yes, whenever value-accretive opportunity aligns with values and helps expand presence in new/existing market.

₹170 Cr debt repayment; ₹150 Cr Vizag hospital stake increase (51% → 85%); ₹50 Cr + ₹95 Cr general corporate purposes.

Depreciation includes North Bangalore and recent capex; ~9% of asset base. Lease expense breakdown deferred.

Strategic reduction of low-margin scheme immunotherapy business in Gujarat. Maharashtra grew >14%. Margins expanding despite growth moderation.

Could have done better on revenue (faced headwinds: price capping, other factors). Margin trajectory has been good. 13–14% growth and margin expansion under headwinds is reasonable.

Very confident. Leverage on maturing centers, clinical differentiation, patient trust. Good position to meet 24–25% EBITDA margins in next few years.

Refrained from center details historically, but number increased. >50% of centers now at 20%+ EBITDA margins.

Operating cash flow before WC changes ~₹125 Cr. Net cash flow from operations ~₹70 Cr.

Price capping impact ~1.5% on revenue; margin-accretive (positive). Cannot quantify margin gain precisely now.

Technology infusion (MR-LINAC, TomoTherapy, surgical robots, CAR-T, BMT, genomics). Recruited specialized physicians to drive case mix improvement.

Do not disclose quarterly; annual disclosure only. Directionally, improved sequentially and YoY.

Long-term aspiration: 21–22% in next 2 years; 24–25% in 4–5 years. Very confident given Q1 performance.

Currently 2.9% (up 20% YoY due to North Bangalore). Long-term target 2.5–2.6%.

Payor mix improvement (biggest lever; +200 bps in Q1). Clinical/technology investments (TomoTherapy, MR-LINAC, robots, clinical talent). Operating leverage from maturing centers (EBITDA growth outpacing revenue). North Bangalore loss mitigation as it matures.

Q1 delivered 13.4%, adjusted for 1.5% CGHS/drug impact ≈ 15%. On track but dependent on underlying volume, ARPP stabilization, and new hospital contribution ramping.

Already at 19.4% Q1; >50% of centers at 20%+ margins today. Key levers: payor mix (200 bps Q1), technology investments (MR-LINAC, robots, CAR-T), operating leverage, North Bangalore loss mitigation.

Brownfield (~60% of expansion) lower capex, faster execution. 3 greenfield projects in pipeline (2 quantified: Whitefield end FY28, Maharashtra FY29). Capex discipline emphasized.

ARPP grew only +2% YoY despite payor mix improvement claims. Indicates pricing stagnation or case-mix shift toward lower-margin therapies. If inflation runs 5%+, ARPP will compress in real terms.

North Bangalore (flagship ₹200 Cr+ asset) still pre-revenue-generation. Contributed ₹6.7 Cr in Q1 but management only promises 'peak EBITDA loss in Q1' with vague 'next few quarters' breakeven timeline. If ramp is slower, margin drag persists for 12+ months.

West cluster institutional revenue down >4% YoY; strategic de-emphasis of low-margin scheme immunotherapy business in Gujarat. While margin-accretive, signals customer concentration risk and potential market share loss if not offset by new cash patient acquisition.

NPM of 2.3% vs EBITDA margin 19.4% indicates ~1,200 Cr depreciation/finance cost burden annually. Even with ₹170 Cr debt repayment from rights issue, leverage remains. PAT growth of 175% is from very low base.

Ambitious bed expansion (520 beds in 2 years) coupled with 3 greenfield projects requires flawless execution, staffing, and regulatory approvals. Brownfield is lower risk, but greenfields (Whitefield, Maharashtra) have longer lead times and execution risk.